The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Data-driven medicine in CLL: the CLL treatment infection model
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses his research on data-driven medical approaches, utilizing standardized health data and electronic health records to inform treatment decisions. He mentions the chronic lymphocytic leukemia (CLL) treatment infection model that aims to identify patients at higher risk of immune dysfunction, infections, or cardiac events and offer tailored treatment. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research grants and/or personal fees: Abbvie, Janssen, AZ, Genmab, Beigene, Galapagos, Takeda, CSL Behring, Lily, MSD, Octapharma.
